Welcome to our dedicated page for Nanovibronix SEC filings (Ticker: NAOV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading NanoVibronix鈥檚 SEC disclosures can feel like sorting clinical trials from accounting notes. Every 10-K details FDA clearance milestones for PainShield, UroShield, and WoundShield, yet those critical updates hide inside hundreds of pages. Our platform turns that problem on its head.
Stock Titan鈥檚 AI summarizes each filing the moment it hits EDGAR, delivering plain-English answers to the questions investors actually type into search: 鈥�NanoVibronix annual report 10-K simplified鈥� or 鈥�understanding NanoVibronix SEC documents with AI.鈥� Whether you need the latest NanoVibronix quarterly earnings report 10-Q filing to track PainShield sales, or want NanoVibronix Form 4 insider transactions real-time to see when executives buy shares, the information is ready and translated into actionable insight.
Here鈥檚 what you鈥檒l uncover:
- 10-K & 10-Q 鈥� AI-highlighted revenue trends, R&D spend, and reimbursement risks, perfect for rapid NanoVibronix earnings report filing analysis.
- 8-K 鈥� Material clinical results and distribution agreements, with NanoVibronix 8-K material events explained in context.
- Form 4 鈥� Track NanoVibronix insider trading Form 4 transactions and spot patterns in NanoVibronix executive stock transactions Form 4.
- DEF 14A 鈥� A concise look at NanoVibronix proxy statement executive compensation so you know how leadership is paid.
No more hunting through appendices. With real-time alerts, expert commentary, and AI-powered summaries, NanoVibronix SEC filings explained simply becomes reality鈥攕o you can focus on how low-intensity ultrasound is changing patient care, not on deciphering legalese.
NanoVibronix, Inc. effected a 1-for-10 reverse stock split of its common stock, combining every ten issued or treasury shares into one share while leaving the par value unchanged. The company will not issue fractional shares; any fractional interests will be rounded up to whole shares.
The Reverse Stock Split reduces outstanding shares from 7,968,868 to approximately 796,887 (subject to rounding). Authorized common shares remain 40,000,000. The common stock will trade on a split-adjusted basis on the Nasdaq Capital Market under the existing ticker NAOV, and the company provided a new CUSIP. Outstanding equity awards and plan reserves will be proportionately adjusted per the terms of the 2014 and 2024 plans. The Certificate of Amendment and a press release are filed as exhibits.
NanoVibronix (NAOV) has filed a DEFA14A to correct an error in their previously filed proxy statement for the Special Meeting scheduled for July 11, 2025. The key correction relates to the outstanding preferred stock disclosure as of May 16, 2025 (Record Date).
The corrected share structure includes:
- Common Stock: 2,282,746 shares
- Series G Preferred Stock: 320,348 shares
- Series X Preferred Stock: 57,720 shares
The company clarifies that no Series C, D, E, or F Preferred Stock are outstanding. Each common share carries one vote, with no cumulative voting rights. Stockholders who have already submitted their proxy votes do not need to take action unless they wish to change their vote. The stockholder list will be available for inspection at the company's headquarters for 10 days before the meeting.
NanoVibronix has announced a Special Meeting of Stockholders to be held virtually on July 11, 2025, primarily to vote on a proposed reverse stock split. The company is seeking approval for a reverse split ratio ranging from 1-for-2 to 1-for-50, to be implemented at the Board's discretion within one year of approval.
Key points for consideration:
- The reverse split is preemptively proposed to maintain Nasdaq compliance, as the stock price recently closed below $1.00 on May 28, 2025
- Current shares outstanding: 2,282,746 shares of Common Stock
- Record date for voting eligibility: May 16, 2025
- Meeting will be held virtually at www.virtualshareholdermeeting.com/NAOV2025SM2
The Board recommends voting FOR both the Reverse Stock Split Proposal and the Adjournment Proposal. This strategic move aims to ensure continued Nasdaq listing compliance and maintain market stability for shareholders.
FAQ
What is the current stock price of Nanovibronix (NAOV)?
What is the market cap of Nanovibronix (NAOV)?
